New immune cell shot targets tough cancers in early trial
Disease control
Recruiting now
This early-stage study tests a new cell therapy called NK042 in people with advanced solid tumors that have not responded to standard treatments. The goal is to check if it is safe and to see if it can shrink tumors. About 76 adults aged 18 to 70 will take part, receiving the tre…
Phase: PHASE1 • Sponsor: Shanghai NK Cell Technology Co., LTD • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC